News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ReCor Medical Discloses New Data From Clinical Study of its PARADISE™ Ultrasound Transcatheter Renal Denervation System for Treating Resistant Hypertension


4/9/2012 12:28:45 PM

RONKONKOMA, N.Y.--(BUSINESS WIRE)--ReCor Medical, an emerging medical device company, disclosed today updated data for the REDUCE First-In-Man clinical study of its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation. PARADISE, which is CE-marked, is designed to treat patients with ‘resistant’ hypertension (“HTN”), a major risk factor for cardiovascular disease.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES